对非小细胞肺癌患者进行全面的生物标志物检测对于选择合适的靶向治疗或免疫治疗至关重要。确保及时订购、处理和报告是优化患者治疗效果的关键。然而，多种因素可能会阻止或延迟患者根据全面的生物标志物测试选择治疗方案。这些因素包括获得检测的机会、组织充足性、周转时间以及健康保险覆盖范围和计费做法等问题。周转时间取决于几个后勤和组织处理因素，其中涉及因不同实践而异的机构政策、流程、资源、测试方法和测试算法。在本文中，作者确定了延长生物标志物测试周转时间的关键因素，提出了减少周转时间的策略，并提出了一个流程图，以帮助医生和主要组织利益相关者提高测试效率。© 2024 作者。 《癌症》由 Wiley periodicals LLC 代表美国癌症协会出版。

Comprehensive biomarker testing for patients with non-small cell lung cancer is critical for selecting appropriate targeted therapy or immunotherapy. Ensuring timely ordering, processing, and reporting is key to optimizing patient outcomes. However, various factors can prevent or delay patients from being offered the option of treatment selection based on comprehensive biomarker testing. These factors include problems with access to testing, tissue adequacy, turnaround time, and health insurance coverage and billing practices. Turnaround time depends on several logistical and tissue handling factors, which involve institutional policies, processes, resources, testing methodology, and testing algorithms that vary across different practices. In this article, the authors identify key factors that prolong biomarker testing turnaround time, propose strategies to reduce it, and present a process map to aid physicians and key organizational stakeholders in improving testing efficiency.© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.